Stevanato Group (NYSE:STVN) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research assumed coverage on shares of Stevanato Group (NYSE:STVN) in a research note published on Friday morning, MarketBeat.com reports. The firm issued an outperform rating and a $28.00 target price on the stock.

Separately, Morgan Stanley reissued an “equal weight” rating and issued a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Stevanato Group currently has an average rating of “Moderate Buy” and an average price target of €28.60 ($30.11).

Stevanato Group Stock Up 3.7 %

Shares of NYSE:STVN opened at €23.31 ($24.54) on Friday. The business’s 50-day moving average is €19.67 and its 200 day moving average is €19.68. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group has a 1 year low of €16.56 ($17.43) and a 1 year high of €34.73 ($36.56).

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). The company had revenue of €277.90 million for the quarter, compared to analyst estimates of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 EPS. On average, analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Stevanato Group in the third quarter valued at approximately $84,000. Raymond James Trust N.A. lifted its stake in shares of Stevanato Group by 18.7% in the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after purchasing an additional 1,613 shares during the period. Hardy Reed LLC boosted its holdings in Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock worth $222,000 after buying an additional 840 shares in the last quarter. Lindenwold Advisors INC boosted its holdings in Stevanato Group by 13.5% during the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock worth $239,000 after buying an additional 1,415 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Stevanato Group by 59.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock valued at $219,000 after buying an additional 4,441 shares during the period.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.